Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS10000994HBVENSG00000082701.17protein_codingGSK3BYesNo2932P49841
Q6FI27
TVIS10024344HBVENSG00000082701.17protein_codingGSK3BYesNo2932P49841
Q6FI27
TVIS10029365HBVENSG00000082701.17protein_codingGSK3BYesNo2932P49841
Q6FI27
TVIS30010815HIVENSG00000082701.17protein_codingGSK3BYesNo2932P49841
Q6FI27
TVIS30081188HIVENSG00000082701.17protein_codingGSK3BYesNo2932P49841
Q6FI27
TVIS30080541HIVENSG00000082701.17protein_codingGSK3BYesNo2932P49841
Q6FI27
TVIS30058093HIVENSG00000082701.17protein_codingGSK3BYesNo2932P49841
Q6FI27
TVIS30058094HIVENSG00000082701.17protein_codingGSK3BYesNo2932P49841
Q6FI27
TVIS30058095HIVENSG00000082701.17protein_codingGSK3BYesNo2932P49841
Q6FI27
TVIS30058096HIVENSG00000082701.17protein_codingGSK3BYesNo2932P49841
Q6FI27
TCGA Plot Options
Drug Information
GeneGSK3B
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0001065
UniProt IDP49841
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830